AU2002225681A1 - Yeast-dentritic cell vaccines and uses thereof - Google Patents

Yeast-dentritic cell vaccines and uses thereof

Info

Publication number
AU2002225681A1
AU2002225681A1 AU2002225681A AU2568102A AU2002225681A1 AU 2002225681 A1 AU2002225681 A1 AU 2002225681A1 AU 2002225681 A AU2002225681 A AU 2002225681A AU 2568102 A AU2568102 A AU 2568102A AU 2002225681 A1 AU2002225681 A1 AU 2002225681A1
Authority
AU
Australia
Prior art keywords
yeast
cell vaccines
dentritic cell
dentritic
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225681A
Inventor
Donald Bellgrau
Richard C Duke
Alex Franzusoff
Cara C. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLOBE IMMUNE Inc
University of Technology Corp
Original Assignee
GLOBE IMMUNE Inc
University of Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLOBE IMMUNE Inc, University of Technology Corp filed Critical GLOBE IMMUNE Inc
Publication of AU2002225681A1 publication Critical patent/AU2002225681A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4641—Fungal antigens, e.g. Trichophyton, Aspergillus or Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AU2002225681A 2000-11-15 2001-11-15 Yeast-dentritic cell vaccines and uses thereof Abandoned AU2002225681A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24917300P 2000-11-15 2000-11-15
US60249173 2000-11-15
PCT/US2001/043537 WO2002039951A2 (en) 2000-11-15 2001-11-15 Yeast-dentritic cell vaccines and uses thereof

Publications (1)

Publication Number Publication Date
AU2002225681A1 true AU2002225681A1 (en) 2002-05-27

Family

ID=22942330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225681A Abandoned AU2002225681A1 (en) 2000-11-15 2001-11-15 Yeast-dentritic cell vaccines and uses thereof

Country Status (3)

Country Link
US (4) US7083787B2 (en)
AU (1) AU2002225681A1 (en)
WO (1) WO2002039951A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
EP1569616A2 (en) * 2002-12-04 2005-09-07 Technologies Biolactis Inc. An exopolysaccharides delivery system for active molecules
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
BRPI0613025A2 (en) * 2005-07-11 2010-12-14 Globeimmune Inc composition for reducing resistance to an agent, method for preparing a yeast vehicle and use of the composition
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
TW201412329A (en) * 2006-02-02 2014-04-01 Globeimmune Inc Yeast-based vaccine for inducing an immune response
MX2008012392A (en) 2006-03-27 2008-12-17 Globeimmune Inc Ras mutation and compositions and mehods related thereto.
WO2007133728A1 (en) * 2006-05-12 2007-11-22 The Trustees Of The University Of Pennsylvania Photodynamic therapy-generated mesothelioma vaccine
CA2676783C (en) * 2007-02-02 2016-04-05 Globeimmune, Inc. Improved methods for producing yeast-based vaccines
US20080220023A1 (en) * 2007-03-08 2008-09-11 Stevens David A Antifungal vaccines with saccharomyces cerevisiae
JP5579451B2 (en) 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド Composition for targeted ablation of avoidance of variability in targeted therapy for cancer
EP3061462B1 (en) 2007-07-02 2019-02-27 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
AU2008348260A1 (en) * 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
DE102008057451A1 (en) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Method for oral vaccination by means of recombinant yeasts
KR102019728B1 (en) 2009-04-17 2019-09-09 글로브이뮨 Combination immunotherapy compositions against cancer and methods
JP5913103B2 (en) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ Combinations comprising yeast-based immunotherapy compositions and methods for screening subjects
US9862927B2 (en) * 2010-01-22 2018-01-09 Baylor Research Institute Dendritic cell vaccines
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
ES2696551T3 (en) 2010-12-17 2019-01-16 Globeimmune Inc Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
MX350661B (en) 2011-03-17 2017-09-13 Us Health Yeast-brachyury immunotherapeutic compositions.
PL2691530T3 (en) 2011-06-10 2019-02-28 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9579377B2 (en) 2011-06-14 2017-02-28 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
KR102049928B1 (en) 2011-08-17 2019-11-28 글로브이뮨 Yeast-muc1 immunotherapeutic compositions and uses thereof
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
DE102011121069A1 (en) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vaccination by recombinant yeast by generating a protective humoral immune response against defined antigens
WO2014003853A1 (en) 2012-06-26 2014-01-03 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US9744193B2 (en) * 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP6494511B2 (en) * 2013-09-05 2019-04-03 オービス ヘルス ソリューションズ エルエルシー Particles filled with tumor lysate
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
CN104981258B (en) 2012-12-12 2017-10-20 奥比思健康解决方案有限责任公司 Composition, Its Preparation Method And Use for regeneration
EP2976100B1 (en) 2013-03-19 2020-07-01 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI728239B (en) 2013-03-26 2021-05-21 美商環球免疫公司 Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CN112891522A (en) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 Tumor lysate loaded microparticles
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP2873728A1 (en) 2013-11-18 2015-05-20 Institut Pasteur A subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
EP3129045B1 (en) 2014-04-11 2022-03-02 PCI Biotech AS Method of treating melanoma
CN113419058A (en) * 2014-04-11 2021-09-21 全球免疫股份有限公司 Yeast-based immunotherapy and type I interferon sensitivity
CN107530383A (en) 2015-01-09 2018-01-02 埃图比克斯公司 Method and composition for research of Ebola vaccine inoculation
JP6647315B2 (en) 2015-01-09 2020-02-14 イーチュービクス コーポレイション Methods and compositions for combination immunotherapy
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
KR20180054587A (en) 2015-08-03 2018-05-24 글로브이뮨 Modified yeast-brachyury immunotherapeutic composition
CN106248812A (en) * 2016-06-28 2016-12-21 林海燕 A kind of hepatitis B virus core antigen detection method of content
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
CN107744550A (en) * 2017-10-29 2018-03-02 南宁学院 A kind of composition for preventing and treating mandarin sturgeon trichodinasis and preparation method thereof
DE102017012109A1 (en) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimized host / vector system for the generation of protective mono- and multivalent subunit vaccines based on the yeast Kluyveromyces lactis
WO2019157529A1 (en) 2018-02-12 2019-08-15 10X Genomics, Inc. Methods characterizing multiple analytes from individual cells or cell populations
US20210154250A1 (en) 2018-05-15 2021-05-27 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CN110724181A (en) * 2019-11-18 2020-01-24 维塔恩(广州)医药有限公司 Herpes simplex virus related antigen short peptide and application thereof
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine
CN114796150A (en) * 2021-01-18 2022-07-29 上海交通大学医学院附属仁济医院 Yeast cell membrane encapsulated bacteria and application

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2055847A (en) * 1979-07-30 1981-03-11 Bull F G Process for the production of carrier particles
FR2486400B1 (en) * 1980-07-09 1986-05-30 Univablot MEDICINAL PRODUCTS BASED ON YEAST OR THEIR INSOLUBLE EXTRACTS
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
IE914102A1 (en) * 1990-11-26 1992-06-03 Genetics Inst Expression of pace in host cells and methods of use thereof
JPH07503851A (en) * 1992-02-10 1995-04-27 インターフェロン・サイエンシズ、インコーポレイテッド Improved interferon and its production method from human peripheral blood leukocytes
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
JPH08511007A (en) * 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド Tandem synthetic HIV-1 peptide
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
JP4028900B2 (en) 1996-01-11 2007-12-26 富士通株式会社 Moving picture coding apparatus and moving picture decoding apparatus
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
WO1998033527A2 (en) * 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
DE10112825A1 (en) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040106779A1 (en) * 2002-12-03 2004-06-03 Bigler Douglas E. Modified factor IX preparation
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
MXPA06015234A (en) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Polymer-factor ix moiety conjugates.
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
BRPI0613025A2 (en) 2005-07-11 2010-12-14 Globeimmune Inc composition for reducing resistance to an agent, method for preparing a yeast vehicle and use of the composition
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
TW201412329A (en) 2006-02-02 2014-04-01 Globeimmune Inc Yeast-based vaccine for inducing an immune response
MX2008012392A (en) 2006-03-27 2008-12-17 Globeimmune Inc Ras mutation and compositions and mehods related thereto.
JP5579451B2 (en) 2007-03-19 2014-08-27 グローブイミューン，インコーポレイテッド Composition for targeted ablation of avoidance of variability in targeted therapy for cancer

Also Published As

Publication number Publication date
US20060104986A1 (en) 2006-05-18
US7083787B2 (en) 2006-08-01
US20070166323A1 (en) 2007-07-19
WO2002039951A2 (en) 2002-05-23
US7595060B2 (en) 2009-09-29
US20130052220A1 (en) 2013-02-28
US8221763B2 (en) 2012-07-17
US20090304741A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2001213236A1 (en) Mini-cyclone biocollector and concentrator
AU2001287898A1 (en) Pyrazolopyridines and pyrazolopyridazines as antidiabetics
AU2001237996A1 (en) Thermally and chemically treating cells
AU2001267181A1 (en) Polyubiquitin based hydrogel and uses thereof
AUPR298901A0 (en) Cell suspension preparation technique and device
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AU2002211717A1 (en) Stresscopins and their uses
AU2001272011A1 (en) Siderophores-producing bifidobacteria thereby and uses thereof
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU6635800A (en) Pyridomorphinans, thienomoprhinans and use thereof
AU2001229770A1 (en) Improved research and development process
AU2001229439A1 (en) Bioconjugates and uses thereof
AU7458201A (en) Laminate and use thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU4427201A (en) Noise-abatement structure and its constituting elements
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
AU2002332028A1 (en) Preadipocyte cell strains and uses therefore
AU2001236755A1 (en) Structures and methods for improved capacitor cells
GB0102717D0 (en) Cells and uses therefor
AU2002254161A1 (en) M cell directed vaccines
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof